



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.

Corporate Office: Energy IT Park, Unit A2, 3rd Floor, Unit A, 8th Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai-400 025.

Phone: 022-2439 5200 / 2439 5500 Fax : 022 – 2431 5331/ 24131 5334

CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON MARCH 31, 2020

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Year ended	
		31-03-2020	31-12-2019	31-03-2019	31-03-2020	31-03-2019
		Audited	Unaudited	Audited	Audited	Audited
1	Revenue from Operations	41,686.52	38,495.45	37,914.77	1,64,074.44	1,50,118.70
2	Other Income	287.63	1,602.19	1,528.85	4,934.27	4,022.50
3	Total Income (1+2)	41,974.15	40,097.64	39,443.62	1,69,008.71	1,54,141.20
4	Expenses					
	a. Cost of materials consumed	12,046.50	9,926.20	11,774.30	45,210.43	45,375.37
	b. Purchases of stock-in-trade	2,767.85	2,818.88	2,702.54	11,450.09	10,426.13
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,047.02)	116.46	98.18	252.83	(2,165.74)
	d. Employee benefit expenses	7,989.53	7,355.40	6,758.24	29,378.09	25,797.86
	e. Finance Costs	40.43	85.28	130.82	293.51	456.55
	f. Depreciation and amortization expense	1,669.23	1,654.59	1,140.81	6,509.05	5,482.49
	g. Other Expenses	10,815.60	9,870.20	10,589.31	40,958.54	41,841.01
	Total Expenses (4)	34,282.12	31,827.01	33,194.20	1,34,052.54	1,27,213.67
5	Profit before Exceptional item and Tax (3-4)	7,692.03	8,270.63	6,249.42	34,956.17	26,927.53
6	Exceptional item (Refer note no. 4)	1,000.00	-	-	1,000.00	-
7	Profit before Tax (5-6)	6,692.03	8,270.63	6,249.42	33,956.17	26,927.53
8	Tax expenses	1,605.46	2,053.37	2,031.91	7,141.77	8,721.61
9	Net Profit after Tax for the period (7-8)	5,086.57	6,217.26	4,217.51	26,814.40	18,205.92
10	Other Comprehensive Income (net of Tax)	(240.79)	(7.63)	214.66	(506.42)	29.25
11	Total Comprehensive Income after Tax (9+10)	4,845.78	6,209.63	4,432.17	26,307.98	18,235.17
12	Earning per share (not annualised)					
	(1) Basic	6.39	7.75	5.13	33.70	22.15
	(2) Diluted	6.39	7.75	5.13	33.70	22.15

NOTES

- The above Standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on June 25, 2020.
- The Board of Directors has recommended a final dividend of Rupee 1 per equity share of face value of Rs. 2/- (50%) for the financial year 2019-20. The Company has declared and paid interim dividend of Rs. 10 per equity share of the face value of Rs. 2/- (500%) for the financial year 2019-20 as declared by the Board of Directors at the meeting held on February 20, 2020.
- Indian Accounting Standard (Ind AS) - 116 "Leases" became effective from April 1, 2019 and the Company has adopted the same using modified retrospective transition method where at the date of initial application, the lease liability is measured at the present value of remaining lease payments and right of use asset has been recognised at an amount equal to the lease liability. In the Standalone financial results for the quarter and year ended March 31, 2020, Compensation Rent expenses has changed to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. The effect of adoption of Ind AS 116 on the results for the quarter and year ended March 31, 2020 is not material. To this extent, performance for the quarter and year ended March 31, 2020 is not comparable with previous period results.
- Exceptional item relates to payment of one time compensation ordered by the Supreme Court vide judgement dated 1-4-2020 in appeal filed by the Company against order dated 8-1-2016 passed by the National Green Tribunal. The Supreme Court has, inter alia, set aside the closure of API unit and ordered payment of this compensation on the basis of precautionary principle.
- The Company has assessed the situation of uncertainty prevailing in view of the COVID 19 pandemic and related disruption it has caused across the globe to movement of the people and transportation of goods. Since the Company is in the business of manufacturing and marketing of pharmaceutical products which is categorized as "essential goods", there is no significant adverse impact on the movement of materials and goods. The Company has considered internal and external information while finalizing various estimates and recoverability of assets in relation to its Standalone financial statement up to the date of approval of the Standalone financial statements by the Board of Directors. Management will continue to closely monitor the situation and changes to future economic conditions which may be caused due to COVID 19.

- 6 Consequent to current pandemic, the Company has experienced slowdown in the sales of products in acute segment due to the closure of clinics and use of hospitals largely for COVID-19 patients. This could also impact performance of the new product launches.
- 7 The Company has exercised the option of lower tax rate of 25.168% (inclusive of surcharge and cess) permitted under Section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly Provision for Income tax and deferred tax liabilities for current year are measured as per the appropriate rates prescribed in in the aforesaid section.
- 8 The Company has one reportable segment viz. Pharmaceuticals.
- 9 Figures pertaining to last quarter are balancing figures between audited figures in respect of full financial year and published and reviewed year-to-date figures up to the third quarter of the financial year 2019-20.
- 10 The figures for the previous period(s) have been re-grouped/restated, wherever necessary.
- 11 **STATEMENT OF STANDALONE AUDITED ASSETS AND LIABILITIES AS AT MARCH 31, 2020.**

(Rs. in lakhs)

	Particulars	As at March 31, 2020 Audited	As at March 31, 2019 Audited
	ASSETS		
(I)	Non-current assets		
	(a) Property, Plant and Equipment	56,533.49	54,254.09
	(b) Capital work-in-progress	1,616.69	1,508.99
	(c) Other Intangible assets	1,787.22	957.01
	(d) Financial Assets		
	(i) Investments	20,242.13	22,884.24
	(ii) Loans	28.10	358.86
	(iii) Others	13.23	15.82
	(e) Other non-current assets	353.58	514.99
	TOTAL non current assets	80,574.44	80,494.00
(II)	Current assets		
	(a) Inventories	23,203.82	20,810.42
	(b) Financial Assets		
	(i) Investments	33,381.26	36,064.99
	(ii) Trade receivables	34,423.91	29,985.20
	(iii) Cash and cash equivalents	962.27	1,936.77
	(iv) Bank balances other than (iii) above	194.02	140.03
	(v) Loans	401.88	70.95
	(vi) Others	721.07	1,678.31
	(c) Current Tax Assets (Net)	1,391.19	666.22
	(d) Other current assets	5,847.54	7,459.44
	TOTAL current assets	1,00,526.96	98,812.33
	Total Assets	1,81,101.40	1,79,306.33
	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity Share capital	1,545.64	1,604.73
	(b) Other Equity	1,42,983.44	1,46,851.50
	Total Equity	1,44,529.08	1,48,456.23
	LIABILITIES		
(I)	Non-current liabilities		
	(a) Provisions	738.68	572.89
	(b) Deferred tax liabilities (Net)	5,884.58	7,115.12
	(c) Other non-current financial liabilities	109.37	-
	(d) Other non-current liabilities	596.84	220.29
	TOTAL non current Liabilities	7,329.47	7,908.30
(II)	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	3,203.61	2,579.77
	(ii) Trade payables		
	A) Dues to Micro and Small Enterprises	945.29	787.01
	B) Due to Other than Micro and Small Enterprises	10,189.73	10,345.72
	(iii) Other financial liabilities	11,152.61	6,983.33
	(b) Other current liabilities	2,676.68	1,721.52
	(c) Provisions	472.88	134.09
	(d) Current Tax Liabilities (Net)	602.05	390.36
	TOTAL Current Liabilities	29,242.85	22,941.80
	Total Equity and Liabilities	1,81,101.40	1,79,306.33

12 STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2020

(Rs. in lakhs)

Particulars	2019-20	2018-19
A. Cash Flow from Operating Activities		
Net Profit before Tax	33,956.17	26,927.53
Adjustment For		
Depreciation	6,509.05	5,482.49
Foreign Exchange Fluctuation (Net)	97.10	569.43
Interest Expense	259.46	423.89
(Profit)/ Loss on Sale/Discard of Assets (Net)	(166.24)	(232.84)
Profit on sale of Investment designated as FVTPL	(2,501.30)	(1,545.93)
Net (Gain) / Loss arising from Financial instruments - designated as FVTPL	(1,298.40)	(1,771.53)
Interest Income	(138.53)	(136.46)
Dividend Income	(148.04)	(88.36)
Government Grant	(91.14)	(68.65)
Re-measurement of the defined benefit plan	(676.74)	44.96
Excess provision written back	(416.48)	(7.57)
Provision for Doubtful debts written back	-	(18.92)
Provision for Doubtful debts/ Bad debts	90.52	36.36
Operating Profit Before Working Capital Changes	35,475.43	29,614.40
Adjustment For		
Trade Receivables	(4,392.01)	(565.81)
Other Receivables	2,500.56	1,877.49
Inventories	(2,393.41)	(3,228.98)
Trade Payable	(162.73)	(2,444.44)
Other Payables & Provisions	4,844.59	117.75
Cash Generated From Operations	35,872.43	25,370.41
Direct Taxes Paid (net)	(8,715.26)	(6,107.53)
Net Cash from Operating Activities	27,157.17	19,262.88
B. Cash Flow from Investing Activities		
Purchase of Fixed Assets	(7,172.87)	(4,827.05)
Sale of Fixed Assets	234.22	714.28
Purchase of Investment	(38,267.56)	(42,522.84)
Sale of Investment	47,393.12	43,560.13
(Increase)/Decrease in other bank balances	(53.99)	58.01
Interest Received	136.97	136.40
Dividend Received	148.04	88.36
Net Cash used in Investing Activities	2,417.93	(2,792.71)
C. Cash Flow from Financing Activities		
Buy back of shares including premium	(16,081.90)	(13,102.79)
Proceeds/(Repayment) from/of Short Term Borrowing (Net)	631.40	(5.00)
Interest Paid	(186.49)	(378.29)
Dividend Paid (Including Dividend Distribution Tax)	(14,100.31)	(2,079.45)
Lease Rent payment	(811.09)	-
Net Cash Used in Financing Activities	(30,548.39)	(15,565.53)
Net Increase in Cash and Cash Equivalents	(973.29)	904.64
Cash and Cash Equivalents as at 01.04.19*	1,611.25	708.92
Exchange difference on restatement of foreign currency cash and cash equivalent	(1.29)	(2.31)
Cash and Cash Equivalents as at 31.03.20*	636.67	1,611.25
	(973.29)	904.64

***Cash and Cash Equivalents comprises the following**

Particulars	As at March 31, 2020	As at March 31, 2019
Balances with banks	924.21	607.63
Remittance in Transit	9.95	-
Cash on hand	22.40	19.54
Post Office Saving Account	-	0.60
Fixed Deposits with maturity of less than 3 months	5.71	1,309.00
	962.27	1,936.77
Less : Bank Overdraft	325.60	325.52
Cash and Cash Equivalents	636.67	1,611.25

Note: The Cash Flow Statement is prepared using the " Indirect method" set out in Ind AS 7 - " Statement of Cash Flows".

For J.B. Chemicals & Pharmaceuticals Ltd.



S.B.Mody

Whole time Director (Marketing)

Place : Mumbai
Date : 25/06/2020



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.
 Corporate Office: Energy IT Park, Unit A2, 3rd Floor, Unit A, 8th Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai-400 025.
 Phone: 022-2439 5200 / 2439 5500 Fax : 022 – 2431 5331/ 24131 5334
 CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON MARCH 31, 2020

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Year ended	
		31-03-2020	31-12-2019	31-03-2019	31-03-2020	31-03-2019
		Audited	Unaudited	Audited	Audited	Audited
1	Revenue from Operations	44,356.93	42,863.25	41,891.55	1,77,472.91	1,64,320.04
2	Other Income	317.38	1,637.96	1,565.09	5,066.99	4,143.99
3	Total Income (1+2)	44,674.31	44,501.21	43,456.64	1,82,539.90	1,68,464.03
4	Expenses					
	a. Cost of materials consumed	12,076.57	9,970.78	11,764.90	45,248.04	45,365.97
	b. Purchases of stock-in-trade	3,540.12	5,403.09	3,829.46	18,230.77	16,209.91
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(917.35)	(339.09)	802.70	(399.27)	(1,929.98)
	d. Employee benefit expenses	8,552.51	8,231.58	7,470.22	32,291.67	28,817.59
	e. Finance Costs	49.88	85.32	130.83	302.96	464.85
	f. Depreciation and amortization expense	1,738.93	1,674.86	1,160.03	6,632.23	5,564.20
	g. Other Expenses	11,931.30	10,637.27	11,470.20	44,344.27	45,272.23
	Total Expenses (4)	36,971.96	35,663.81	36,628.34	1,46,650.67	1,39,764.77
5	Profit before Exceptional item and Tax (3-4)	7,702.35	8,837.40	6,828.30	35,889.23	28,699.26
6	Exceptional item (Refer note no. 4)	1,000.00	-	-	1,000.00	-
7	Profit before Tax (5-6)	6,702.35	8,837.40	6,828.30	34,889.23	28,699.26
8	Tax expenses	1,695.26	2,192.72	2,149.27	7,650.02	9,302.29
9	Net Profit after Tax for the period (7-8)	5,007.09	6,644.68	4,679.03	27,239.21	19,396.97
10	Other Comprehensive Income (net of Tax)	(1,813.43)	696.45	276.20	(1,497.61)	(419.64)
11	Total Comprehensive Income after Tax (9+10)	3,193.66	7,341.13	4,955.23	25,741.60	18,977.33
12	Net Profit after Tax for the period attributable to:					
	- owners of the company	5,013.93	6,627.72	4,665.71	27,204.71	19,346.63
	- non controlling interest	(6.84)	16.96	13.32	34.50	50.34
13	Other comprehensive income for the period attributable to :					
	- owners of the company	(1,737.89)	671.00	277.67	(1,432.88)	(372.44)
	- non controlling interest	(75.54)	25.45	(1.47)	(64.73)	(47.20)
14	Total Comprehensive Income after Tax attributable to:					
	- owners of the company	3,276.04	7,298.72	4,943.38	25,771.83	18,974.19
	- non controlling interest	(82.38)	42.41	11.85	(30.23)	3.14
15	Earning per share (not annualised)					
	(1) Basic	6.30	8.26	5.68	34.20	23.54
	(2) Diluted	6.30	8.26	5.68	34.20	23.54

NOTES

- The above Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on June 25, 2020.
- The Board of Directors has recommended a final dividend of Rupee 1 per equity share of face value of Rs. 2/- (50%) for the financial year 2019-20. The Company has declared and paid interim dividend of Rs. 10 per equity share of the face value of Rs. 2/- (500%) for the financial year 2019-20 as declared by the Board of Directors at the meeting held on February 20, 2020.

- 3 Indian Accounting Standard (Ind AS) - 116 "Leases" became effective from April 1, 2019 and the Group has adopted the same using modified retrospective transition method where at the date of initial application, the lease liability is measured at the present value of remaining lease payments and right of use asset has been recognised at an amount equal to the lease liability. In the Consolidated financial results for the quarter and year ended March 31, 2020, Compensation Rent expenses has changed to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. The effect of adoption of Ind AS 116 on the results for the quarter and year ended March 31, 2020 is not material. To this extent, performance for the quarter and year ended March 31, 2020 is not comparable with previous period results.
- 4 Exceptional item relates to payment of one time compensation ordered by the Supreme Court vide judgement dated 1-4-2020 in appeal filed by the Holding Company against order dated 8-1-2016 passed by the National Green Tribunal. The Supreme court has, inter alia, set aside the closure of API unit and ordered payment of this compensation on the basis of precautionary principle.
- 5 The Group has assessed the situation of uncertainty prevailing in view of the COVID 19 pandemic and related disruption it has caused across the globe to movement of the people and transportation of goods. Since the Group is in the business of manufacturing and marketing of pharmaceutical products which is categorized as "essential goods", there is no significant adverse impact on the movement of materials and goods. The Group has considered internal and external information while finalizing various estimates and recoverability of assets in relation to its Consolidated financial statement up to the date of approval of the Consolidated financial statements by the Board of Directors. Management will continue to closely monitor the situation and changes to future economic conditions which may be caused due to COVID 19.
- 6 Consequent to current pandemic, the Group has experienced slowdown in the sales of products in acute segment due to the closure of clinics and use of hospitals largely for COVID-19 patients. This could also impact performance of the new product launches.
- 7 The Holding Company has exercised the option of lower tax rate of 25.168% (inclusive of surcharge and cess) permitted under Section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly Provision for Income tax and deferred tax liabilities for current year are measured as per the appropriate rates prescribed in the aforesaid section.
- 8 The Consolidated financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements.
- 9 The Group has one reportable segment viz. Pharmaceuticals.
- 10 Figures pertaining to last quarter are balancing figures between audited figures in respect of full financial year and published and reviewed year-to-date figures up to the third quarter of the financial year 2019-20.
- 11 The figures for the previous period(s) have been re-grouped/restated, wherever necessary.
- 12 **STATEMENT OF CONSOLIDATED AUDITED ASSETS AND LIABILITIES AS AT MARCH 31, 2020.**

(Rs. in lakhs)

Particulars	As at	As at
	March 31,2020	March 31,2019
	Audited	Audited
ASSETS		
(I) Non-current assets		
(a) Property, Plant and Equipment	56,802.98	54,441.67
(b) Capital work-in-progress	1,616.69	1,508.99
(c) Goodwill	5,314.00	5,314.00
(d) Other Intangible assets	3,009.24	2,337.75
(e) Financial Assets		
(i) Investments	6,945.45	9,587.56
(ii) Loans	28.10	358.86
(iii) Others	13.23	15.82
(f) Other non-current assets	353.58	514.99
TOTAL non current assets	74,083.27	74,079.64
(II) Current assets		
(a) Inventories	27,466.97	24,375.77
(b) Financial Assets		
(i) Investments	33,381.26	36,064.99
(ii) Trade receivables	34,542.62	30,822.36
(iii) Cash and cash equivalents	2,900.79	3,539.68
(iv) Bank balances other than (iii) above	194.02	140.03
(v) Loans	421.22	140.23
(vi) Others	721.07	1,707.19
(c) Current Tax Assets (Net)	1,564.00	715.06
(d) Other current assets	6,080.89	7,609.91
TOTAL current assets	1,07,272.84	1,05,115.22
Total Assets	1,81,356.11	1,79,194.86

EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	1,545.64	1,604.73
(b) Other Equity	1,42,003.29	1,46,407.51
(c) non controlling interest	250.10	280.33
Total Equity	1,43,799.03	1,48,292.57
LIABILITIES		
(I) Non-current liabilities		
(a) Provisions	738.68	572.89
(b) Deferred tax liabilities (Net)	4,814.04	5,690.73
(c) Other non-current financial liabilities	122.92	-
(d) Other non-current liabilities	596.84	220.29
TOTAL non current Liabilities	6,272.48	6,483.91
(II) Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	3,203.61	2,579.77
(ii) Trade payables		
A) Dues to Micro and Small Enterprises	945.29	787.01
B) Due to Other than Micro and Small Enterprises	11,433.96	10,950.45
(iii) Other financial liabilities	11,710.49	7,558.87
(b) Other current liabilities	2,677.82	1,750.89
(c) Provisions	711.38	397.72
(d) Current Tax Liabilities (Net)	602.05	393.67
TOTAL Current Liabilities	31,284.60	24,418.38
Total Equity and Liabilities	1,81,356.11	1,79,194.86

13 **CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2020**

(Rs. in lakhs)

Particulars	2019-20	2018-19
A. Cash Flow from Operating Activities		
Net Profit before Tax	34,889.23	28,699.26
Adjustment For		
Depreciation	6,632.23	5,564.20
Unrealised Foreign Exchange Fluctuation (Net)	(633.04)	267.69
Interest Expense	268.91	432.20
(Profit)/ Loss on Sale/Discard of Assets (Net)	(178.75)	(244.70)
Profit on sale of Investment designated as FVTPL	(2,501.30)	(1,545.93)
Net (Gain) / Loss arising from Financial instruments - designated as FVTPL	(1,298.40)	(1,771.53)
Interest Income	(262.10)	(229.58)
Dividend Income	(148.04)	(88.36)
Government Grant	(91.14)	(68.65)
Re-measurement of the defined benefit plan	(676.74)	44.96
Excess provision written back	(416.48)	(9.32)
Provision for Doubtful debts written back	-	(18.92)
Provision for Doubtful debts/ Bad debts	100.34	39.98
Operating Profit Before Working Capital Changes	35,684.72	31,071.30
Adjustment For		
Trade Receivables	(3,683.38)	(1,387.68)
Other Receivables	2,496.34	2,458.59
Inventories	(3,091.20)	(3,002.62)
Trade Payable	476.77	(2,857.12)
Other Payables & Provisions	4,733.87	(358.41)
Cash Generated From Operations	36,617.11	25,924.06
Direct Taxes Paid (net)	(9,079.94)	(6,491.47)
Net Cash from Operating Activities	27,537.17	19,432.59


B. Cash Flow from Investing Activities		
Purchase of Fixed Assets	(7,296.77)	(4,912.01)
Sale of Fixed Assets	246.73	732.30
Purchase of Investment	(38,267.56)	(42,522.84)
Sale of Investment	47,393.12	43,560.13
(Increase)/Decrease in other bank balances	(53.99)	58.01
Interest Received	260.69	229.52
Dividend Received	148.04	88.36
Net Cash used in Investing Activities	2,430.27	(2,766.53)
C. Cash Flow from Financing Activities		
Buy back of shares	(16,081.90)	(13,102.79)
Proceeds/(Repayment) from/of Short Term Borrowing (Net)	631.40	(5.00)
Interest Paid	(186.50)	(386.60)
Dividend Paid (Including Dividend Distribution Tax)	(14,100.31)	(2,079.45)
Lease Rent payment	(867.82)	-
Net Cash Used in Financing Activities	(30,605.13)	(15,573.84)
Net Increase in Cash and Cash Equivalents	(637.68)	1,092.22
Cash and Cash Equivalents as at 01.04.19*	3,214.16	2,124.25
Exchange difference on restatement of foreign currency cash and cash equivalent	(1.29)	(2.31)
Cash and Cash Equivalents as at 31.03.20*	2,575.19	3,214.16
	(637.68)	1,092.22

*Cash and Cash Equivalents comprises the following

Particulars	As at March 31, 2020	As at March 31, 2019
Balances with banks	2,862.31	1,996.92
Remittance in Transit	9.95	-
Cash on hand	22.82	20.02
Post Office Saving Account	-	0.60
Fixed Deposits with maturity of less than 3 months	5.71	1,522.14
	2,900.79	3,539.68
Less : Bank Overdraft	325.60	325.52
Cash and Cash Equivalents	2,575.19	3,214.16

Note: The Consolidated Cash Flow Statement is prepared using the " Indirect method" set out in Ind AS 7 - " Statement of Cash Flows".

For J.B. Chemicals & Pharmaceuticals Ltd.



S.B.Mody

Whole time Director (Marketing)

Place : Mumbai

Date : 25/06/2020